Cellectar Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Cellectar Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cellectar Biosciences Inc Strategy Report
- Understand Cellectar Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Cellectar Biosciences Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 16 Sep 2022 | A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma | Grant |
National Cancer Institute US
|
Cellectar Biosciences Inc |
| 31 Aug 2022 | An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia | Grant |
National Cancer Institute US
|
Cellectar Biosciences Inc |
| 28 Aug 2021 | An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia | Grant |
National Cancer Institute US
|
Cellectar Biosciences Inc |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer